<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9925">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916005</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00056-39</org_study_id>
    <secondary_id>2013-01</secondary_id>
    <nct_id>NCT01916005</nct_id>
  </id_info>
  <brief_title>Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis</brief_title>
  <official_title>Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of prosthetic valve endocarditis (PVE) remains challenging. In PVE cases,
      initial echocardiography is normal or inconclusive in almost 30% of cases, leading to a
      decreased diagnostic accuracy for the modified Duke criteria.

      Aims: The investigators sought to determine the value of 18F-fluorodeoxyglucose positron
      emission tomography/computed tomography (18F-FDG PET/CT) for diagnosing PVE.

      Methods: In two referral French centers (Timone Hospial, Marseille and Georges Pompidou
      European Hospital, Paris), the investigators plan to include consecutive patients suspected
      of having PVE. All of the patients will be subjected to clinical, microbiological, and
      echocardiographic evaluation. Cardiac PET/CT will be performed at admission and the data
      analysis will be based on visual interpretation and quantitative measurement of FDG uptake
      (SUVmax). The final diagnosis will be defined according to the clinical and/or pathological
      modified Duke criteria determined during a 3-month follow-up (gold standard).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>the diagnosis of prosthetic valve infective endocarditis</measure>
    <time_frame>39months</time_frame>
    <safety_issue>No</safety_issue>
    <description>18F-fluorodeoxyglucose positron emission tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the reproducibility of the technique,</measure>
    <time_frame>39 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the other diagnostic parameters of PET/CT (specificity and predictive values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the comparison of the sensitivity of PET/CT with that of echocardiography,</measure>
    <time_frame>39 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>the other diagnostic parameters of PET/CT (specificity and predictive values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of detection of embolic events,</measure>
    <time_frame>39 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>the other diagnostic parameters of PET/CT (specificity and predictive values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prognostic value of the technique (death/valve surgery)</measure>
    <time_frame>39 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>the other diagnostic parameters of PET/CT (specificity and predictive values)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Prosthetic Valve Endocarditis (PVE)</condition>
  <arm_group>
    <arm_group_label>endocarditis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>18F-FDG PET/CT</intervention_name>
    <arm_group_label>endocarditis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unexplained persistent or recurrent fever &gt;38°C;

          -  and/or unexplained increased serum C-reactive protein (CRP) level &gt;10 mg/L; and/or
             positive blood cultures, independent of the echocardiographic analysis results;

          -  and/or  positive serological testing for Coxiella burnetii, Bartonella spp.,
             Mycoplasma pneumoniae, Legionella pneumophila, Aspergillus spp., or Tropheryma
             whipplei;

          -  and/or a mass or a new partial prosthetic valve dehiscence observed using
             echocardiography.

        Exclusion Criteria:

          -  pregnancy,

          -  an inability to lie flat,

          -  a need for urgent cardiac surgery,

          -  hemodynamic instability,

          -  cardiac surgery &lt;1 month ago,

          -  and a blood glucose level &gt;1.8 g/L. Patients with a poor PET/CT image quality
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>FRANCK THUNY</last_name>
    <email>franck.thuny@aphm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>franck thuny</last_name>
      <email>franck.thuny@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>franck THUNY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
